Skip to main content
SpringerLink
Log in

Moxonidine Effect on Microalbuminuria, Thrombomodulin, and Plasminogen Activator Inhibitor-1 Levels in Patients with Essential Hypertension

  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

Abstract

Increased sympathetic activity seems to play an important role in the pathogenesis and development of complications of atherosclerotic origin in patients with essential hypertension (EH). The aim of this study was to evaluate the effect of a new antihypertensive agent, moxonidine (M), on microalbuminuria (urine albumin excretion, UAE), plasma thrombomodulin (TM), and tissue plasminogen activator inhibitor (PAI-1) in patients with mild to moderate EH associated with increased UAE. Fifty-eight patients (32 M, 26 F) with EH and microalbuminuria, with a mean age of 56.6 ± 8.2 years and a body mass index (BMI) of 23.8 ± 3.1 kg/m2 who responded to M therapy (0.3–0.4 mg/daily) were studied before and after their blood pressure control. The 24-hour urine albumin excretion (RIA method), as well as TM and PAI-1 plasma levels (ELISA method), were determined before and 6 months after the initiation of treatment under moxonidine therapy. At the end of the 6-month period, all patients remained normotensive. The 24-hour urine albumin excretion had decreased to 24.5 ± 6.4 vs. 32.3 ± 7.2 ug/min before therapy (P < 0.001). The plasma TM levels had decreased to 44.0 ± 7 vs. 51.0 ± 9 ng/mL before therapy (P < 0.01), and PAI-1 levels had also decreased to 11.5 ± 4.5 vs. 15.8 ± 8 IU/mL before therapy (P < 0.05). The results of our study suggest that in hypertensive patients with microalbuminuria, moxonidine, an imidazoline I1-receptor agonist, a new centrally acting antihypertensive agent, significantly reduces urine albumin excretion as well as thrombomodulin and PAI-1 levels. These preliminary findings demonstrate a favorable effect on renal function and endothelial homeostatic mechanisms (maintenance of haemostatic balance).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Bigazzi R, Bianchi S, Campese VM, Baldani G. Prevalence of microalbuminuria in a large population of patients with mild to moderate essential hypertension. Nephron 1992; 61:94-97.

    Google Scholar 

  2. Sammerson JH, Bell RA, Koney JC. Racial differences in prevalence of microalbuminuria in hypertension. Am J Kidney Dis 1995;26:577-579.

    Google Scholar 

  3. Parwing HH, Gyntelberg F. Transcapillary escape rate of albumin and plasma volume in essential hypertension. Circ Res 1973;33:643-653.

    Google Scholar 

  4. Yudkin JS, Forrest RD, Jackson CA. Microalbuminuria predictor of vascular disease in nondiabetic subjects. Lancet 1988;2:531-534.

    Google Scholar 

  5. Ruilope LM, Rodicio JL. Microalbuminuria in clinical practice. Kidney Curr Surv, World Literature 1995;4:211-216.

    Google Scholar 

  6. Kuuisto J, Mykkayen L, Pyorala K, Laakso M. Hyperinsulinemic microalbuminuria, a new risk indicator for coronary heart disease. Circulation 1995;91:831-837.

    Google Scholar 

  7. Damsgaard EM, Froland A, Jorgensen OD, Mogensen CE. Microalbuminuria as predictor of increased mortality in elderly people. Br Med J 1990;300:297-300.

    Google Scholar 

  8. Jaffe EA. Cell biology of endothelial cells. Hum Pathol 1987;18:234-239.

    Google Scholar 

  9. Borsum T. Biochemical properties of vascular endothelial cells. Virchows Arch (B), Cell Pathol 1991;60:279-286.

    Google Scholar 

  10. Giddings JC. Endothelial cell biology and haemostasis. Br J Biomed Sci 1993;50:43-47.

    Google Scholar 

  11. Pearson JD. Vessel wall interactions regulating thrombosis. Br Med Bull 1994;50:776-788.

    Google Scholar 

  12. Blann DA, Taberner AD. A reliable marker of endothelial cell dysfunction: Does it exist? Br J Haematol 1995;90: 244-248.

    Google Scholar 

  13. Parwing HH. Microalbuminuria in essential hypertension and diabetes mellitus. J Hypertens 1996;14(Suppl. 2): S89-S94.

    Google Scholar 

  14. Luscher TF, Noll G. Endothelial function as an end-point in interventional trials. J Hypertens 1996;14(Suppl. 2): S111-S121.

    Google Scholar 

  15. Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure. The fifth report of the Joint National Committee on Detection, Evaluation of High Blood Pressure (JNC-V). Arch Intern Med 1993;153:154-83.

    Google Scholar 

  16. Pedrinelli R, Di Bello VA, Catapano G, et al. Microalbuminuria is a marker of left ventricular hypertophy but not hyperinsulinemia in nondiabetic atherosclerotic patients. Atherosclerosis 1993;13:900-906.

    Google Scholar 

  17. Viberti GC. Mechanisms of diabetic renal and cardiovascular disease. Acta Diabetol 1990;27:267-276.

    Google Scholar 

  18. European Concerted Action on Thrombosis and Disabilities (ECAT). Euglobulin clot lysis time. In: Jespersen J, Bertina RM, Haverkate F. Kluwe, eds. ECAT Assay Procedures Handbook. Dordrecht, 1992:125-129.

  19. Amiral J, Adam M, Mimilia F, Larrivaz I, Chambrette B, Boffa MC. A new assay for soluble forms of thrombomodulin in plasma. Thromb Haemost 1991;65:947.

    Google Scholar 

  20. United States Renal Data System: VSRDS 1991. Annual Data Report. Bethesda, MD. National Institute of Diabetes and Digestive and Kidney Diseases, 1992.

  21. Valderrabano F, Jones EHP, Mallick NP. Report of management of renal failure in Europe. Nephrol Dial Transplant 1995;10(Suppl. 5):1-25.

    Google Scholar 

  22. Rodicio JL. Does antihypertensive therapy protect the kidney in essential hypertension? J Hypertens 1996;14(Suppl. 2):S69-S76.

    Google Scholar 

  23. Parving HH, Morgensen CE, Jensen HAE, Ervin PE. Increased urinary albumin excretion rate in benign essential hypertension. Lancet 1974;I:1190-1192.

    Google Scholar 

  24. Redon J, Liao Y, Lozano JV, Miralles A, Baldo E, Cooper RS. Factors related to the presence of microalbuminuria in essential hypertension. Am J Hypertens 1994;7:801-807.

    Google Scholar 

  25. Cerasola G, Cottone S, D'lgnoto G et al. Microalbuminuria as a predictor of cardiovascular damage in essential hypertension. J Hypertens 1989;7(Suppl. 6):S332-S333.

    Google Scholar 

  26. Bianchi S, Bigazzi R, Baldori G, Campese VM. Microalbuminuria in patients with essential hypertension: Effects of several antihypertensive drugs. AmJ Med 1992; 93:525-528.

    Google Scholar 

  27. Erley C, Haefete V, Heyne N, Baran N, Rister T. Microalbuminuria in essential hypertension: Reduction by different antihypertensive drugs. Hypertension 1993;21:810-815.

    Google Scholar 

  28. Rosen P, Ohly P, Gleichmann H. Experimental benefit of moxonidine on glucose metabolism and insulin secretion in the fructose-fed rat. J Hypertens 1997;15(Suppl. 1):S31-S38.

    Google Scholar 

  29. Ruilope LM, Alcazar JM, Hernandez E, et al. Long-term influences of antihypertensive therapy on microalbuminuria in essential hypertension. Kidney Int 1994;45(Suppl. 45):S171-S173.

    Google Scholar 

  30. Hamsten A. The haemostatic system and coronary heart disease. Thromb Res 1993;70:1-38.

    Google Scholar 

  31. Pearson JD. Vessel wall interactions regulating thrombosis. Br Med Bull 1994;50:776-788.

    Google Scholar 

  32. Landin K, Tengborn L, Smith U. Elevated fibrinogen and plasminogen activator inhibitor (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease. J Intern Med 1990;227:273-278.

    Google Scholar 

  33. Jansson JH, Johanson B, Boman K, et al. Hypofibrinolysis in patients with hypertension and elevated cholesterol. J Intern Med 1991;229:309-316.

    Google Scholar 

  34. Van Wersch JW, Rompelberg-Lahaye J, Lustermans FA. Plasma concentrations of coagulation and fibrinolysis factors and platelet function in hypertension. Eur J Clin Chem Clin Biochem 1991;29:375-379.

    Google Scholar 

  35. Glueck CJ, Glueck HI, Hamer T, et al. Beta blockers, Lp(a), hypertension and reduced basal fibrinolytic activity. Am J Med Sci 1994;307:317-324.

    Google Scholar 

  36. Gader AM, da Costa J, Parker SM et al. The systemic release of plasminogen activator to intravenous adrenaline in man: Dose response studies. Thromb Res 1973;3:51-57.

    Google Scholar 

  37. Ishi H, Majerus PW. Thrombomodulin is present in human plasma and urine. J Clin Invest 1985;76:2178-2184.

    Google Scholar 

  38. Seigneur M, Dufourcq P, Conri C, et al. Levels of plasma thrombomodulin are increased in atheromatous arterial disease. Thromb Res 1993;71:423-431.

    Google Scholar 

  39. Makris T, Krespi P, Votteas V, et al. Thrombomodulin and TFPI levels in patients with arterial hypertension. Eur Heart J 1997;18(Suppl. 599):85.

    Google Scholar 

  40. Takahashi H, Tatewaki W, Wada K, et al. DDAVP does not induce the release of thrombomodulin from endothelial cells. Thromb Haemost 1991;65:451.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department, of Cardiology, 2nd Reg. BTC, Athens University, Medical School, Greece

    Panagiota G. Krespi, Thomas K. Makris, Antonios N. Hatzizacharias, Philippos Triposkiadis, Catherine Tsoukala, Despina Kyriaki, Vassilios Votteas & Michael Kyriakidis

  2. Haemostasis Lab, Department of Nuclear Medicine, “LAIKON” General Hospital, Athens, Greece

    Panagiota G. Krespi

Authors
  1. Panagiota G. Krespi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thomas K. Makris
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Antonios N. Hatzizacharias
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Philippos Triposkiadis
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Catherine Tsoukala
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Despina Kyriaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Vassilios Votteas
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Michael Kyriakidis
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Krespi, P.G., Makris, T.K., Hatzizacharias, A.N. et al. Moxonidine Effect on Microalbuminuria, Thrombomodulin, and Plasminogen Activator Inhibitor-1 Levels in Patients with Essential Hypertension. Cardiovasc Drugs Ther 12, 463–467 (1998). https://doi.org/10.1023/A:1007702132210

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1007702132210

Search

Navigation